Drug Type Small molecule drug |
Synonyms Cefbuperazone, Cefbuperazone sodium (JP17), BMY-25182 + [3] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors), Cell wall inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization- |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date- |
Regulation- |
Molecular FormulaC22H29N9NaO9S2 |
InChIKeyHKFFDVOEBVRKTD-FDVIUCIPSA-N |
CAS Registry76648-01-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01736 | Cefbuperazone Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bacterial Infections | - | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Respiratory Tract Infections | Phase 3 | CN | 04 Feb 2015 | |
Urinary Tract Infections | Phase 3 | CN | 04 Feb 2015 | |
Bronchiectasis | Phase 1 | CN | 20 Dec 2017 | |
Bronchiectasis | Phase 1 | CN | 20 Dec 2017 | |
Bronchitis, Chronic | Phase 1 | CN | 20 Dec 2017 | |
Bronchitis, Chronic | Phase 1 | CN | 20 Dec 2017 | |
Lymphadenitis | Phase 1 | CN | 20 Dec 2017 | |
Lymphadenitis | Phase 1 | CN | 20 Dec 2017 | |
Parametritis | Phase 1 | CN | 20 Dec 2017 | |
Parametritis | Phase 1 | CN | 20 Dec 2017 |